Maintenance prescriptions at diagnosis.

<p>Patients (n = 3199) prescribed maintenance therapy at baseline and 3–6 months excluding patients with no treatment, SABD alone, ICS, and others. Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist.</p

Percent of patients that progressed to triple therapy within 2 years by index treatment prescribed.

<p>Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LABD, long-acting bronchodilator; LAMA, long-acting muscarinic antagonist; SABD, short-acting bronchodilator.</p><p>Percent of patients that progressed to triple therapy within 2 years by index treatment prescribed.</p

Proportions of patients continuing on the same treatment class for 24 months.

<p>^a To be included in analysis, patients had to receive a prescription at each 3-month interval. Triple, LABA+LAMA+ICS. Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist.</p

Percentage of changes in maintenance medications at the end of the 24 months of follow-up.

<p>Censored indicates no prescription for a COPD maintenance medication during a 3 month interval.</p

Proportions of patients switching to another medication or stepping down treatment.

a<p>To be included in analysis, patients had to receive a prescription at each 3-month interval.</p><p>Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.</p><p>Proportions of patients switching to another medication or stepping down treatment.</p

Proportions of patients adding to medication.

a<p>Number of patients starting/remaining on treatment at the beginning of the year.</p><p>Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.</p><p>Proportions of patients adding to medication.</p

Prevalence and Burden of Dyspnoea Among Patients with Chronic Obstructive Pulmonary Disease in Five European Countries

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s41030-016-0011-5">https://link.springer.com/article/10.1007/s41030-016-0011-5</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p